Salah-Eddin Al-Batran
Heidelberg University
293 Papers
2.3K Citations
Salah-Eddin Al-Batran is an academic researcher from Heidelberg University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 45, co-authored 238 publications.
Chat about Author
Papers
Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.
Thorsten Oliver Goetze,Daniel Wilhelm Mueller,Mohammad-Reza Rafiyan,Dragan Kiselicki,Regina Eickhoff,Elke Jaeger,Salah-Eddin Al-Batran +6 more
TL;DR: The INSPIRATION study investigates the feasibility and safety of s.c. application of IMP321 (eftilagimod alpha) combined with the PD-L1 inhibitor avelumab in advanced stage oncology with promising results.
7
Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie.
Deniz Gencer,Felix Tauchert,Nina Keilhauer,Salah-Eddin Al-Batran,Michael Stahl,Gülten Oskay-Özcelik,Matthias Hipp,Birgit Leibbrand,Nicole Prasnikar,Tanja Trarbach,Christoph Stoll,Michael van Kampen,Andreas Hochhaus,Sylvie Lorenzen,Ralf-Dieter Hofheinz +14 more
TL;DR: Young patients, especially younger patients in good health status with higher education degrees indicated their willingness to use internet QoL assessment tools, and these data may serve as a basis for identifying patient groups willing to participate in pilot projects to evaluate the implementation of internet-based regular assessment ofQoL in cancer.
7
Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2−advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.
Manish A. Shah,Jaffer A. Ajani,Salah-Eddin Al-Batran,Yung-Jue Bang,Daniel V.T. Catenacci,Peter C. Enzinger,David H. Ilson,Sunnie Kim,Florian Lordick,Kohei Shitara,Eric Van Cutsem,Ahsan M. Arozullah,Jung Wook Park,Rui-Hua Xu +13 more
TL;DR: The once-weekly treatment with capecitabine + oxaliplatin (CAPOX) is a standard first-line treatment for advanced gastric cancer and reduces the need for chemotherapy by up to 70% in patients with advanced cancer.
7
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO.
Sylvie Lorenzen,Peter C. Thuss-Patience,Claudia Pauligk,Eray Goekkurt,Thomas J. Ettrich,Florian Lordick,Michael Stahl,Peter Reichardt,Martin Soekler,Daniel Pink,Stephan Probst,Hana Algül,Axel Hinke,Thorsten Oliver Goetze,Salah-Eddin Al-Batran +14 more
TL;DR: Ramucirumab as monotherapy and in combination with paclitaxel is a proven second-line option for advanced gastroesophageal adenocarcinoma (GEA).
7
Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.
Salah-Eddin Al-Batran,Sylvie Lorenzen,Michael Schenk,Peter C. Thuss-Patience,Eray Goekkurt,Ralf Hofheinz,Albrecht Kretzschmar,Claus Bolling,S. Angermeier,Andreas Wicki,Alexander Rheinhard Siebenhuener,Ekkehard Eigendorff,Christin Pink,Thomas J. Ettrich,Harald Schmalenberg,Lisa Waberer,Jonathan Talbot,Claudia Pauligk,Thorsten Oliver Goetze,Nils Homann +19 more
TL;DR: In this article, the authors evaluated atezolizumab in the perioperative treatment of locally advanced, potentially resectable gastric or GEJ adenocarcinoma in combination with FLOT.
7